slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 22,501-22,530
Pages 885
Rows per page 30
Arc
22,501-22,530 of 26,550
26
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
27
The slide uses a three-column icon-based layout to summarize key IP milestones.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
28
The slide uses a grid layout to display headshots and names for the executive team, and a list format for the board of directors with associated company logos.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
29
The slide combines a financial summary with a timeline of milestones and a value proposition for their lead asset.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
05
Includes a personal testimonial/case study image of a patient (Shay) to humanize the disease.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a biological mechanism-of-action illustration to show how the drug components interact with specific cellular stressors.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
08
Includes a process diagram for iPSC generation and two charts: a survival curve and a hazard ratio bar chart.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
09
The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
Study identifier NST002, 15 patients, open-label, intermediate formulation.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
11
Includes details on screen failures and co-treatment with Riluzole.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
12
Uses numbered icons for primary/secondary and a lightbulb icon for exploratory.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
Includes a footnote citation for the methodology definitions.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
17
The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
18
The slide uses icons to represent functional domains and provides specific clinical examples of what a 1-point change means for patient quality of life.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
19
The chart visualizes the reduction in point loss, highlighting the efficacy of PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
20
The slide uses a human silhouette to categorize ALS symptoms into four domains, then presents bar charts for each domain comparing treatment vs placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
24
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
03
The slide uses a combination of metrics and a growth chart to frame the market opportunity and the severity of the problem.Talkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Talkspace | Investor Conference Presentation Deck | 13 slidesTalkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Uses a before-after framing to establish the problem (left) and the solution/impact (right).Talkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · DesireLoop · Cost Of Inaction1 hit
08
Talkspace | Investor Conference Presentation Deck | 13 slidesTalkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · Interest1 hit
09
Includes screenshots of a research paper and a press release as evidence.Talkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
10
The slide uses a grid of cards to present quantitative improvements in EBITDA, Opex, network growth, covered lives, and session volume, alongside a qualitative milestone.Talkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
11
Talkspace | Investor Conference Presentation Deck | 13 slidesTalkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
12
The slide uses a combination of market sizing data and demographic behavioral data to justify a product launch.Talkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
13
Includes company logo, conference name, presenter names, and date.Talkspace | Investor Conference Presentation Deck | 13 slides · Talkspace
Conference presentation Investor relations Beat · Impact & Next Steps1 hit